Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HTX Spins Off New Company (Australia)

This article was originally published in PharmAsia News

Executive Summary

Australian diagnostics company, HealthLinx, is in the process of setting up a new subsidiary focused on drug research and development. The subsidiary, called Proaegis Biosciences, is designed to further treatments for acute respiratory distress syndrome and ulcerative colitis. Already HealthLinx has in-licensed patents for drugs to treat each condition to Proaegis. The treatments, CR014 and Follistatin, are expected to enter Phase I clinical trials soon. HealthLinx plans to retain a 36 percent interest in the new company. In the meantime, the company has already raised $1 million of the $5 million it is hoping to retain through initial investors. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts